CellMed AG is a
BTG International group company
CellMed AG
Our Programmes
An encapsulated stem cell product (CellBead® Neuro) in development for the treatment of neurological trauma and neurological degeneration.
A cosmetic dermatology programme, focused on the dermal filler market segment which comprises of two dermal filler products and an enzyme which allows in-vivo-dissolution.
A Glucagon-Like Peptide-1 analogue in clinical development for the treatment of type 2 diabetes and obesity.
HB Test is a Haemoglobin test kit for point-of-care-testing of the haemoglobin level in human blood. It is primarily sold to blood banks and doctors' surgeries.
CellMed AG, a BTG International group company, is located in Alzenau, Germany. Our research and development teams are using their expertise in the areas of biopolymer science and stem cell biology to develop innovative regenerative medicine products across multiple therapeutic areas. Our therapeutic development programs include a cell therapy product for intracerebral haemorrhage (ICH) stroke, dermal filling products for multiple aesthetic indications, a novel delivery vehicle for both drug and cell-based therapies and CM3, a peptide to treat type 2 diabetes.
BTG, our parent company, is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders.
News
Read the latest Press Releases from BTG
